Segment, Geographic and Other Revenue Information - Revenues By Products (Detail) $ in Millions		3 Months Ended
		Apr. 03, 2016 USD ($) Operating_Segment Operating_segments	Mar. 29, 2015 USD ($)
Revenue from External Customer [Line Items]
Revenues	[1],[2]	$ 13,005	$ 10,864
Number of operating segments | Operating_segments		3
Global Innovative and Established Pharmaceutical [Member] | Lyrica [Member]
Revenue from External Customer [Line Items]
Revenues	[3]	$ 1,229	1,187
Global Innovative and Established Pharmaceutical [Member] | Viagra [Member]
Revenue from External Customer [Line Items]
Revenues	[4]	396	396
Global Innovative and Established Pharmaceutical [Member] | Alliance revenues [Member]
Revenue from External Customer [Line Items]
Revenues		360	222
Innovative Products Business [Member]
Revenue from External Customer [Line Items]
Revenues	[5]	$ 7,033	5,738
Number of operating segments | Operating_segments		2
Innovative Products Business [Member] | Innovative Products [Member]
Revenue from External Customer [Line Items]
Number of operating segments | Operating_Segment		2
Innovative Products Business [Member] | Global Innovative Pharmaceutical [Member]
Revenue from External Customer [Line Items]
Revenues	[5]	$ 3,640	3,075
Innovative Products Business [Member] | Global Innovative Pharmaceutical [Member] | Lyrica [Member]
Revenue from External Customer [Line Items]
Revenues	[3]	1,011	846
Innovative Products Business [Member] | Global Innovative Pharmaceutical [Member] | Enbrel (Outside the U.S. and Canada) [Member]
Revenue from External Customer [Line Items]
Revenues		733	759
Innovative Products Business [Member] | Global Innovative Pharmaceutical [Member] | Viagra [Member]
Revenue from External Customer [Line Items]
Revenues	[4]	300	288
Innovative Products Business [Member] | Global Innovative Pharmaceutical [Member] | Chantix / Champix [Member]
Revenue from External Customer [Line Items]
Revenues		220	158
Innovative Products Business [Member] | Global Innovative Pharmaceutical [Member] | Xeljanz [Member]
Revenue from External Customer [Line Items]
Revenues		197	96
Innovative Products Business [Member] | Global Innovative Pharmaceutical [Member] | BeneFIX [Member]
Revenue from External Customer [Line Items]
Revenues		185	173
Innovative Products Business [Member] | Global Innovative Pharmaceutical [Member] | ReFacto AF/ Xyntha [Member]
Revenue from External Customer [Line Items]
Revenues		129	120
Innovative Products Business [Member] | Global Innovative Pharmaceutical [Member] | Genotropin [Member]
Revenue from External Customer [Line Items]
Revenues		125	138
Innovative Products Business [Member] | Global Innovative Pharmaceutical [Member] | Toviaz [Member]
Revenue from External Customer [Line Items]
Revenues		64	63
Innovative Products Business [Member] | Global Innovative Pharmaceutical [Member] | Somavert [Member]
Revenue from External Customer [Line Items]
Revenues		55	49
Innovative Products Business [Member] | Global Innovative Pharmaceutical [Member] | B M P 2 [Member]
Revenue from External Customer [Line Items]
Revenues		51	38
Innovative Products Business [Member] | Global Innovative Pharmaceutical [Member] | Rapamune [Member]
Revenue from External Customer [Line Items]
Revenues		45	53
Innovative Products Business [Member] | Global Innovative Pharmaceutical [Member] | Alliance revenues [Member]
Revenue from External Customer [Line Items]
Revenues	[6],[7]	354	200
Innovative Products Business [Member] | Global Innovative Pharmaceutical [Member] | All Other Biopharmaceutical Products [Member]
Revenue from External Customer [Line Items]
Revenues		171	92
Innovative Products Business [Member] | Global Vaccines, Oncology and Consumer Healthcare [Member]
Revenue from External Customer [Line Items]
Revenues	[5]	3,394	2,664
Innovative Products Business [Member] | Global Vaccines, Oncology and Consumer Healthcare [Member] | All Other Biopharmaceutical Products [Member]
Revenue from External Customer [Line Items]
Revenues		117	63
Innovative Products Business [Member] | Global Vaccines, Oncology and Consumer Healthcare [Member] | Prevenar family [Member]
Revenue from External Customer [Line Items]
Revenues		1,509	1,306
Innovative Products Business [Member] | Global Vaccines, Oncology and Consumer Healthcare [Member] | Ibrance [Member]
Revenue from External Customer [Line Items]
Revenues		429	38
Innovative Products Business [Member] | Global Vaccines, Oncology and Consumer Healthcare [Member] | Sutent [Member]
Revenue from External Customer [Line Items]
Revenues		278	242
Innovative Products Business [Member] | Global Vaccines, Oncology and Consumer Healthcare [Member] | Xalkori [Member]
Revenue from External Customer [Line Items]
Revenues		139	111
Innovative Products Business [Member] | Global Vaccines, Oncology and Consumer Healthcare [Member] | Inlyta [Member]
Revenue from External Customer [Line Items]
Revenues		101	95
Innovative Products Business [Member] | Global Vaccines, Oncology and Consumer Healthcare [Member] | Consumer Healthcare [Member]
Revenue from External Customer [Line Items]
Revenues		822	808
Established Products Business [Member]
Revenue from External Customer [Line Items]
Revenues	[8]	5,972	5,125
Legacy Established Products [Member] | Established Products Business [Member]
Revenue from External Customer [Line Items]
Revenues	[9]	2,800	2,848
Legacy Established Products [Member] | Established Products Business [Member] | Global Established Pharmaceutical [Member] | Lipitor [Member]
Revenue from External Customer [Line Items]
Revenues		411	441
Legacy Established Products [Member] | Established Products Business [Member] | Global Established Pharmaceutical [Member] | Premarin family [Member]
Revenue from External Customer [Line Items]
Revenues		256	232
Legacy Established Products [Member] | Established Products Business [Member] | Global Established Pharmaceutical [Member] | Norvasc [Member]
Revenue from External Customer [Line Items]
Revenues		236	252
Legacy Established Products [Member] | Established Products Business [Member] | Global Established Pharmaceutical [Member] | Epi Pen [Member]
Revenue from External Customer [Line Items]
Revenues		97	76
Legacy Established Products [Member] | Established Products Business [Member] | Global Established Pharmaceutical [Member] | Xalatan Xalacom [Member]
Revenue from External Customer [Line Items]
Revenues		89	102
Legacy Established Products [Member] | Established Products Business [Member] | Global Established Pharmaceutical [Member] | Zithromax / Zmax [Member]
Revenue from External Customer [Line Items]
Revenues		80	79
Legacy Established Products [Member] | Established Products Business [Member] | Global Established Pharmaceutical [Member] | Zoloft [Member]
Revenue from External Customer [Line Items]
Revenues		79	86
Legacy Established Products [Member] | Established Products Business [Member] | Global Established Pharmaceutical [Member] | Relpax [Member]
Revenue from External Customer [Line Items]
Revenues		78	80
Legacy Established Products [Member] | Established Products Business [Member] | Global Established Pharmaceutical [Member] | Effexor [Member]
Revenue from External Customer [Line Items]
Revenues		70	73
Legacy Established Products [Member] | Established Products Business [Member] | Global Established Pharmaceutical [Member] | Tikosyn [Member]
Revenue from External Customer [Line Items]
Revenues		61	37
Legacy Established Products [Member] | Established Products Business [Member] | Global Established Pharmaceutical [Member] | Xanax/Xanax XR [Member]
Revenue from External Customer [Line Items]
Revenues		52	54
Legacy Established Products [Member] | Established Products Business [Member] | Global Established Pharmaceutical [Member] | Cardura [Member]
Revenue from External Customer [Line Items]
Revenues		45	52
Legacy Established Products [Member] | Established Products Business [Member] | Global Established Pharmaceutical [Member] | Neurontin [Member]
Revenue from External Customer [Line Items]
Revenues		44	55
Legacy Established Products [Member] | Established Products Business [Member] | Global Established Pharmaceutical [Member] | Other Legacy Established Products [Member]
Revenue from External Customer [Line Items]
Revenues	[7],[9]	1,201	1,229
Peri-LOE Products [Member] | Established Products Business [Member] | Global Established Pharmaceutical [Member]
Revenue from External Customer [Line Items]
Revenues	[10]	1,090	1,437
Peri-LOE Products [Member] | Established Products Business [Member] | Global Established Pharmaceutical [Member] | Lyrica [Member]
Revenue from External Customer [Line Items]
Revenues	[3]	218	341
Peri-LOE Products [Member] | Established Products Business [Member] | Global Established Pharmaceutical [Member] | Viagra [Member]
Revenue from External Customer [Line Items]
Revenues	[4]	96	108
Peri-LOE Products [Member] | Established Products Business [Member] | Global Established Pharmaceutical [Member] | Pristiq [Member]
Revenue from External Customer [Line Items]
Revenues		178	161
Peri-LOE Products [Member] | Established Products Business [Member] | Global Established Pharmaceutical [Member] | Celebrex [Member]
Revenue from External Customer [Line Items]
Revenues		172	205
Peri-LOE Products [Member] | Established Products Business [Member] | Global Established Pharmaceutical [Member] | Vfend [Member]
Revenue from External Customer [Line Items]
Revenues		156	182
Peri-LOE Products [Member] | Established Products Business [Member] | Global Established Pharmaceutical [Member] | Zyvox [Member]
Revenue from External Customer [Line Items]
Revenues		127	271
Peri-LOE Products [Member] | Established Products Business [Member] | Global Established Pharmaceutical [Member] | Revatio [Member]
Revenue from External Customer [Line Items]
Revenues		66	63
Peri-LOE Products [Member] | Established Products Business [Member] | Global Established Pharmaceutical [Member] | All Other Peri-LOE Products [Member]
Revenue from External Customer [Line Items]
Revenues		76	107
Sterile Injectable Pharmaceuticals [Member] | Established Products Business [Member] | Global Established Pharmaceutical [Member]
Revenue from External Customer [Line Items]
Revenues	[11]	1,524	729
Sterile Injectable Pharmaceuticals [Member] | Established Products Business [Member] | Global Established Pharmaceutical [Member] | Medrol [Member]
Revenue from External Customer [Line Items]
Revenues		113	87
Sterile Injectable Pharmaceuticals [Member] | Established Products Business [Member] | Global Established Pharmaceutical [Member] | Sulperazon [Member]
Revenue from External Customer [Line Items]
Revenues		96	98
Sterile Injectable Pharmaceuticals [Member] | Established Products Business [Member] | Global Established Pharmaceutical [Member] | Fragmin [Member]
Revenue from External Customer [Line Items]
Revenues		78	74
Sterile Injectable Pharmaceuticals [Member] | Established Products Business [Member] | Global Established Pharmaceutical [Member] | Tygacil [Member]
Revenue from External Customer [Line Items]
Revenues		76	74
Sterile Injectable Pharmaceuticals [Member] | Established Products Business [Member] | Global Established Pharmaceutical [Member] | All Other Sterile Injectable Pharmaceuticals [Member]
Revenue from External Customer [Line Items]
Revenues		1,161	396
Infusion Systems [Member] | Established Products Business [Member] | Global Established Pharmaceutical [Member]
Revenue from External Customer [Line Items]
Revenues	[12]	304	0
Biosimilars [Member] | Established Products Business [Member] | Global Established Pharmaceutical [Member]
Revenue from External Customer [Line Items]
Revenues	[13]	66	0
CentreOne [Member] | Established Products Business [Member] | Global Established Pharmaceutical [Member]
Revenue from External Customer [Line Items]
Revenues	[14]	$ 188	111
Adjustment [Member] | CentreOne [Member] | Established Products Business [Member] | Global Established Pharmaceutical [Member]
Revenue from External Customer [Line Items]
Revenues			$ 111

[1] Amounts may not add due to rounding.

[2] On September 3, 2015, we acquired Hospira. Commencing from the acquisition date, our condensed consolidated statement of income includes the operating results of Hospira. As a result, legacy Hospira operations are included in our condensed consolidated statements of income for the first quarter of 2016, but not for the first quarter of 2015. See Note 2A for additional information.

[3] Lyrica revenues from all of Europe, Russia, Turkey, Israel and Central Asia countries are included in Lyrica-GEP. All other Lyrica revenues are included in Lyrica-GIP. Total Lyrica revenues represent the aggregate of worldwide revenues from Lyrica-GIP and Lyrica-GEP.

[4] Viagra revenues from the U.S. and Canada are included in Viagra-GIP. All other Viagra revenues are included in Viagra-GEP. Total Viagra revenues represent the aggregate of worldwide revenues from Viagra-GIP and Viagra-GEP.

[5] The Innovative Products business is composed of two operating segments: GIP and VOC.

[6] Includes Eliquis and Rebif.

[7] Total Alliance revenues represent the aggregate of worldwide revenues from Alliance revenues GIP and Alliance revenues GEP, which is included in All other Legacy Established Products.

[8] The Established Products business consists of GEP, which includes all legacy Hospira commercial operations. Hospira's commercial operations, including the legacy Hospira One-2-One sterile injectables contract manufacturing business, are included in GEP’s operating results in our condensed consolidated statement of income commencing from the acquisition date of September 3, 2015. As a result, revenues for the first quarter of 2015 and GEP's revenues for the first quarter of 2015 do not include Hospira's revenues. Also, effective as of the beginning of 2016, our entire contract manufacturing business, Pfizer CentreOne, is now part of GEP. Pfizer CentreOne consists of (i) legacy Pfizer's contract manufacturing and active pharmaceutical ingredient sales operation, including our manufacturing and supply agreements with Zoetis Inc. (previously known as Pfizer CentreSource or PCS); and (ii) legacy Hospira's One-2-One sterile injectables contract manufacturing operation. Prior to 2016, PCS was managed outside our operating segments and its revenues were reported as other business activities. We have reclassified prior period PCS revenues ($111 million in the first quarter of 2015) to conform to the current period presentation as part of GEP.

[9] Legacy Established Products include products that have lost patent protection (excluding Sterile Injectable Pharmaceuticals and Peri-LOE Products).

[10] Peri-LOE Products include products that have recently lost or are anticipated to soon lose patent protection. These products primarily include Celebrex and Zyvox in most developed markets, Lyrica in certain developed Europe markets, Pristiq globally and Inspra in the EU.

[11] Sterile Injectable Pharmaceuticals include generic injectables and proprietary specialty injectables (excluding Peri-LOE Products).

[12] Infusion Systems include Medication Management Systems products composed of infusion pumps and related software and services, as well as I.V. Infusion Products, including large volume I.V. solutions and their associated administration sets.

[13] Biosimilars include Inflectra (biosimilar infliximab) in certain European markets, Nivestim (biosimilar filgrastim) in certain Asian markets and Retacrit (biosimilar epoetin zeta) in certain international markets.

[14] Pfizer CentreOne includes (i) revenues from legacy Pfizer's contract manufacturing and active pharmaceutical ingredient sales operation, including revenues related to our manufacturing and supply agreements with Zoetis Inc. (previously known as Pfizer CentreSource or PCS); and (ii) revenues from legacy Hospira’s One-2-One sterile injectables contract manufacturing operation. For additional information, see (e) above.